Updated results from a phase III trial of sunitinib versus placebo in patients with progressive, unresectable, well-differentiated pancreatic neuroendocrine tumor (NET).

Authors

Aaron Vinik

EVMS Strelitz Diabetes Research Center and Neuroendocrine Unit, Norfolk, VA

Aaron Vinik , Eric Van Cutsem , Patricia Niccoli , Jean-Luc Raoul , Yung-Jue Bang , Ivan Borbath , Juan W. Valle , Peter Metrakos , Denis Smith , Jen-Shi Chen , Dieter Hoersch , Daniel E. Castellano , Hagen F. Kennecke , Joel Picus , Guy Van Hazel , Shem Patyna , Dongrui (Ray) Lu , Richard C. Chao , Eric Raymond

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2012 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Other GI Cancer

Clinical Trial Registration Number

NCT00428597; NCT00443534; NCT00428220

Citation

J Clin Oncol 30, 2012 (suppl; abstr 4118)

DOI

10.1200/jco.2012.30.15_suppl.4118

Abstract #

4118

Poster Bd #

50E

Abstract Disclosures

FEATURED

Updated results from a phase III trial of sunitinib versus placebo in patients with progressive, unresectable, well-differentiated pancreatic neuroendocrine tumor (NET).

Authors

Aaron Vinik

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Poster Details

Meeting

Session Type

Session Title

Track

Sub Track

Clinical Trial Registration Number

Citation

DOI

Abstract #

Poster Bd #

Similar Posters

Poster

Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET).

Poster

Evaluation of progression-free survival by blinded independent central review in patients with progressive, well-differentiated pancreatic neuroendocrine tumors treated with sunitinib or placebo.

Poster

Trial in progress: A phase 3, randomized, double-blind trial of trilaciclib versus placebo in patients receiving first- or second-line gemcitabine and carboplatin for locally advanced unresectable or metastatic triple-negative breast cancer (PRESERVE 2).

Poster

Subgroup analysis by Ki-67 and baseline CgA of the randomized, placebo-controlled phase 3 study of surufatinib in advanced well-differentiated pancreatic neuroendocrine tumors (SANET-p).